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Thursday, March 6 
10:30 - 11:30 Studio 2014  
jointly organised by Siemens Healthcare 
and Bayer HealthCare  
SY 1  
Beyond imaging in breast MR: innovation 
and workflow optimisation in clinical 
practice  
Moderator  
L. Moy; New York, NY/US  
MR vacuum assisted biopsies and contrast injection optimisation  
F. Stöblen; Essen/DE  
Purpose: Visualisation of suspicious lesions in breast MRT for the MR-steered 
biopsy utilising an optimised contrasting protocol. Typically, the contrast-
enhanced MR visualisation of breast lesions with a single contrast agent 
administration is marred by a swift enhancement and an equally swift washout, 
resulting in an unfavourably short period of reliable focus delineation. 
Consequently, the biopsy based on such findings will be error prone, since the 
region of interest may have shifted after imaging or been erroneously identified 
in the first place. Since the reliable identification of relatively small foci is the 
main objective of contrast-enhanced breast MRT, these shortcomings seriously 
impair the method’s explanatory power with respect to the important 
discrimination between benign and malignant lesions. The present study seeks 
to establish a protocol that provides the best possible diagnostic value in 
interventional contrast MRT-based breast lesion biopsy evaluation. Methods 
and Materials: MRT methods employed included ‘reference’ (single 
administration of 0.1 mMol/kg body weight, n = 11), ‘single maximum dosage’ 
(n = 11), ‘continuously low’ (n = 10), ‘continuously high’ (n = 13), and 
‘intermittent’ (n = 9). MRT findings of 54 breast cancers by two different 
experienced examiners were evaluated. Both examiners rated the items ‘image 
quality’ (verbal rating scale [VRS] good - 1, average - 2, poor - 3), 
‘visualisation’ (excellent - 1, good - 2, moderate - 3, poor - 4, no - 5), and 
‘confidence of diagnosis’ (very confident - 1, confident - 2, not confident - 3, not 
confident at all - 4). Ratings of both examiners were assessed in terms of inter- 
and intra-rater reliability. Results: As compared to the reference (quality-
controlled pathology), continuously low dosage yielded the best results (i. e. 
highest agreement between both examiners and the reference standard) 
across experimental conditions. Conclusion: Continuously low dosage might 
be the most explanatory examination modality for the MRT-guided 
interventional examination of breast lesions employing contrast-enhanced 
MRT.  
Economic aspects and the future of breast MR  
C.G.N. Kaiser; Mannheim/DE  
Purpose: The purpose of this study is to evaluate the economic aspects (cost 
vs. savings) of the use of MR with dense breasts as additional indication. 
Methods and Materials: The study included 1488 patients after dropout 
between 04/2006 and 12/2011. As result we found 76 true-positive cases 
(invasive cancers and/or DCIS), 48 false-positive cases, 971 true-negative 
cases and 0 false-negative cases. The true-negative findings were either 
confirmed by histology upon recommendation of an external institution (18 
patients) or follow-up by MRM or patient questionnaires over the next 5 years 
by mail (1737 cases). 393 patients were lost to follow-up. Results: The overall 
costs for patients (MRM examinations, biopsies and costs of limited surgeries) 
included in this study resulted in expenses to the amount of € 1.53 Mio. (€ 
1.187 Mio. MRM cost + € 304.000 for further treatment of true-positive findings 
+ € 48.000 for the biopsy of 48 false-positive findings). On the contrary, the 
estimate amount of savings (prevented biopsies, reduced surgeries) ranged 
from € 2.65 Mio to € 4.15 Mio (€ 2.15 Mio in prevented biopsies and treatment 
+ 76 true-positive findings, resulting in a total of € 0,5 - 2 Mio. in less extensive 
treatment). This results in savings for the insurance company of € 1.1 Mio. - € 
2.6 Mio., i.e. a cost reduction of at least 50% could be achieved, in case MRM 
was performed under high-quality conditions (i.e. high specificity through 
reader experience) in dense breasts.  
Learning Objectives: 
1. To learn appreciate the economic value and monetary benefits of MRM, 
analysing the cost reduction through the alteration of diagnostics and 
treatment. 
2. To understand that optimal technical standards and reader experience seem 
inevitable prerequisites for the future adaption of MR indications. 
3. To learn about MR-Mammography, though feasible, is probably not ready for 
"screening" today. 
Simultaneous acquisition of breast imaging with PET/MRI a powerful tool 
to better classify lesions  
L. Moy; New York, NY/US  
Breast MRI is a helpful adjunct tool to detect mammographically and 
sonographically occult breast cancer. It has been used extensively to screen 
high-risk women; especially BRCA mutation carriers and to assess the extent 
of disease in women with known breast cancer. It is also used to assess 
response to neo-adjuvant chemotherapy. However, there is room for 
improvement because breast MRI has a very high sensitivity and a lower 
specificity. At NYU, we are fortunate to have recently acquired a molecular MRI 
that uses a 3 Tesla magnet and simultaneously acquires PET events. The 
Siemens Biograph mMR offers the fused advantages of PET and MRI without 
radiation of CT.  
Learning Objectives: 
1. To review our localised breast PET/MR protocol and to share our preliminary 
results. 
2. To discuss how breast PET/MR may be useful in the evaluation of breast 
lesions. 
3. To discuss adjunctive tools from PET/MR that may increase specificity of the 
exam and provide additional information using a multi-parametric approach. 
Panel discussion  
 
12:00 - 13:30 Studio 2014  
jointly organised by Siemens Healthcare 
and Bayer HealthCare  
SY 2  
Multimodality lunch symposium: what 
does a breast imaging system have to 
perform?  
Moderator  
H. Bosmans; Leuven/BE  
3D automated breast ultrasound: accuracy and diagnostic potentials  
M.J.C.M. Rutten; s-Hertogenbosch/NL  
Automated 3D breast ultrasound (US) is a new technique, which scans the 
breast automatically and almost entirely. Data sets can be stored and are 
available for 3D cross-correlating review. This new technique may eliminate the 
subjectivity of conventional 2D ultrasound and disconnect the acquisition and 
assessment of US data. It facilitates the possibility of double reading, review of 
follow-up studies and the application of computer-aided detection. Issues to be 
discussed are: 1. implementation of automated 3D breast ultrasound in the 
clinical radiological setting; 2. technique of reading and interpretation of 3D US 
data sets; 3. standardisation of assessment and reproducibility (e.g. CAD and 
reading software); 4. diagnostic yield, sensitivity and specificity and factors 
influencing these, such as limitations, artefacts, pitfalls and errors due to 
irrationality.  
Learning Objectives: 
1. To learn how to implement 3D breast US in daily practice. 
2. To become familiar with reading technique and software. 
3. To comprehend the limitations of 3D breast ultrasound. 
2D FFDM vs 3D DBT, with special respect to syngo.breast care and 
optimised workflow, possibilities and challenges with 2D FFDM vs 3D 
DBT  
S.H. Heywang-Köbrunner; Munich/DE  
FFDM technology has made significant progress since its introduction, when 
equivalence to conventional mammography was still doubtful. Today, excellent 
resolution and optimized contrast are achieved at lower dosages than is 
possible with conventional mammography. Regular availability of previous films 
is very helpful. To take full advantage of the digital technology, image display 
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and logistics (e.g. hanging protocols) of the reading should be optimized in 
each department or practice and should be supported by the manufacturer. 
Further optimisation might include automated density measurement and 
automated export of density measurements (which might in the future be useful 
as risk predictor). Limitations which still need to be considered are as follows: 
1) Though contrast has been optimized, there are still differences in the 
contrast between vendors and even with changing algorithms of the same 
vendor. Readers should be aware of such pitfalls. 2) To date, no 
standardization exists for image contrast or automated density measurements. 
So, thresholds cannot be transferred. Tomosynthesis (TS) promises further 
important improvement of sensitivity and specificity, particularly in the 
screening situation. Furthermore, it may allow more accurate density 
measurement. However, TS is associated with increasing reading time and 
possibly even increased reader fatigue. Studies on the latter topic are lacking. 
To date, comparability of TS between the vendors is not yet established. 
Considering the importance of previous studies (which usually are 2D FFDM), 
either 2D reconstructions or 3D rendering may be of great importance for 
reading logistics. Due to increasing possibilities, which are associated with 
increasing demands to the readers, efforts to optimize reading logistics and 
research for CAD support s should be encouraged.  
Learning Objectives: 
1. To learn about optimising reading logistics of FFDM. 
2. To learn about pitfalls to remember (comparability of contrast or 
measurements). 
3. To become familiar with possibilities of tomosynthesis and topics for its 
implementation. 
Breast lesion detection and characterisation with MRI in less than two 
minutes  
R.M. Mann; Nijmegen/NL  
Breast MRI is highly sensitive for the detection of breast cancer. Nevertheless, 
it also detects many benign lesions that would otherwise have gone unnoticed. 
In our efforts to increase the specificity of breast MRI, in recent years many 
additions to the basic breast MRI protocol have been proposed. These include 
T2, diffusion-weighted imaging and spectroscopy. Although proven effective, 
this lengthens the scan protocol and makes MRI more expensive. Due to the 
recent improvement in the image quality of very fast dynamic series, it is now 
possible to document contrast inflow in the tumour at a high spatial resolution. 
This allows monitoring of the inflow phase rather than the outflow phase. In 
over two years of clinical practice, we have not discovered a single lesion that 
was visible on the conventional contrast-enhanced acquisitions, but was occult 
on the inflow evaluation. Parameters derived from this evaluation, time to 
enhancement and maximum slope are much stronger discriminators between 
benign and malignant disease than the conventional BIRADS curves. 
Consequently, also specificity is increased. In contrast to conventional 
approaches, the time to enhancement is linked to the tumour grade and hence 
also allows an approximation of important histopathologic parameters. Very 
recent improvements include a further increased spatial resolution, CAD based 
on fast dynamic evaluation, as well as the addition of Dixon, thus enabling fast 
dynamic fat-saturated imaging. It is therefore possible to limit the dynamic 
evaluation to the inflow only, shortening the scan protocol to approximately 2 
minutes. This highly increases the feasibility of breast MRI as a screening tool.  
What the radiologist need to know in order to have breast MR referrals  
N.N.  
Despite the use of breast MR since 30 years (since 1983), there are still a lot of 
controversial reasons for the acceptance or refusal of breast MR. The best 
case has very high sensitivity AND specificity so as not to get many false 
positives. For that, the radiologist must verify that he has a lot of experience, 
especially knowledge of many morphological and kinetic signs to differentiate 
between benign and malignant lesions. A radiologist doing breast MR should 
not have more than 2% false-positive biopsies. There is still not consensus for 
this. Therefore, a variety of reasons have to be understood to be really helpful 
to the patients.  
Panel discussion  
 
 
12:30 - 13:30 Room L/M  
organised by SuperSonic Imagine  
SY 3  
The benefits UltraFast™ imaging bring to 
ultrasound  
The Ultrafast ultrasound revolution: current and future applications  
M. Tanter; Paris/FR  
ShearWave™ elastography of solid breast lesions: benign versus 
malignant differentiation and prediction of disease behavior  
A. Evans; Dundee/UK  
The advances of liver ultrasound imaging and innovative ShearWave™ 
elastography  
C.F. Dietrich; Bad Mergentheim/DE  
The advantages and clinical Impacts of ShearWave™ elastography in 
prostate imaging  
J. Walz; Marseille/FR  
 
12:30 - 13:30 Room N/O  
organised by Bayer Healthcare  
SY 4  
Optimising contrast: thank you for your 
attenuation!  
Moderator  
J.E. Wildberger; Maastricht/NL  
Prelude. The recipe.  
J.E. Wildberger; Maastricht/NL  
Enhance! The clinics.  
M. Forsting; Essen/DE  
Encore. The outlook.  
U.J. Schoepf; Charleston, SC/US  
 
14:00 - 15:30 Studio 2014  
organised by Siemens Healthcare  
SY 5  
Digital breast tomosynthesis and low dose 
mammography: how innovations 
compliment clinical routine  
Moderator  
S.H. Heywang-Köbrunner; Munich/DE  
Digital breast tomosynthesis: from a first idea to clinical routine  
J. Barkhausen; Lübeck/DE  
Mammography is the most important breast imaging technique allowing the 
visualisation of masses and micro-calcifications. However, in conventional 
mammography, the three-dimensional breast tissue is reduced to a two-
dimensional image and a small lesion may be undetectable due to 
superimposed glandular tissue. Therefore, immediately after the introduction of 
whole body computed tomography, several groups investigated the new 
imaging technique for the detection of breast cancer. However, due to limited 
spatial resolution and the high radiation exposure, the technique never made it 
into daily clinical practice. These limitations were overcome with the 
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development of high-resolution digital mammography and in 1997 the first 
results of limited angle tomography using a full-field digital mammographic 
system were published by Niklason. The prototype scanner was optimised 
within the next decade and digital breast tomosynthesis is now commercially 
available in clinical routine. 7 to 30 low-dose mammographic projections are 
performed over a limited angle of up to 60 degrees and based on these images 
a stack of cross-sectional images covering the entire breast is reconstructed 
with an interslice distance of about 1 mm. The glandular dose of a 
tomosynthesis scan is higher than one-view mammography, but significantly 
lower compared to a standard mammography in two projections. Recently, 
several large clinical trials have shown that tomosynthesis improves tumour 
detection as well as the characterisation of focal masses. DBT adds important 
information to standard two-projection mammography and the encouraging 
results warrant further clinical investigation in large trials.  
Learning Objectives: 
1. To understand the technical basics of digital breast tomosynthesis (DBT). 
2. To learn about hard- und software developments to optimise DBT. 
3. To discuss current indications and future applications of DBT 
Technical optimisation of digital breast tomosynthesis for future breast 
screening  
P. Timberg; Malmö/SE  
Digital breast tomosynthesis (DBT) is considered a promising alternative to 
digital mammography (DM). Screening trials are investigating the performance 
of DBT compared to DM and in combination with DBT. If DBT is to be 
implemented in screening, many technical challenges in DBT remain to 
improve image quality and reading conditions. This presentation will focus on 
studies on different acquisition schemes, reading time, the use of slabbing of 
reconstructed slices, different image reconstructions and viewing conditions 
(frame rates and image orientation). This will be exemplified by studies from 
our research group and others. A second topic is breast compression. Can 
reduced compression be used in DBT and how is actually the pressure 
distribution over the breast during compression? Is compression harmful and is 
there a risk of tumour cell shedding?  
Learning Objectives: 
1. To become familiar with digital breast tomosynthesis, which faces 
challenges in reading time. 
2. To understand that slabbing is a promising choice to reduce data and 
reading time. 
3. To understand that breast compression can be significantly improved. 
Is DBT the new standard in the diagnostic imaging of the breast? How to 
implement DBT as a method in specialist training?  
C. Van Ongeval; Leuven/BE  
In the early reports on tomosynthesis (DBT), an improvement in both sensitivity 
and specificity in lesion detection and characterization was found compared to 
2D imaging. Meanwhile, DBT has been introduced in screening and 
preliminary reports suggest a reduction in recall rate which is mainly correlated 
to a better characterization of the mass lesions. While the introduction of a new 
technique in screening is time-consuming, the introduction in the diagnostic 
work is much more direct. Notwithstanding the fact that DBT is already used in 
some clinical practices, questions on the performance of DBT in the different 
tasks of diagnostic imaging remain: 1) Can DBT replace additional views? 2) 
Can DBT predict better the correct diameter and amount of lesions 
preoperatively compared to 2D imaging? 3) Can DBT evaluate more accurately 
the surgical scar and surrounding breast tissue in a treated breast? 4) Is DBT 
better in the evaluation of dense breasts in high-risk patients? In case of 
screening with digital mammography, 8 h of theoretical and practical training 
was advised and applied by many countries. Gur et al. already showed in 2009 
that training in DBT reading can result in a better performance of DBT. 
Therefore, additional training should be advised not only in screening, but also 
in diagnostic implementation of DBT.  
Learning Objectives: 
1. To learn about the advantages of DBT in diagnostic imaging of the breast. 
2. To become familiar with the strength and weaknesses in relation to mass 
lesion and microcalcifications diagnosis. 
3. To appreciate the impact of training in reading DBT. 
High image quality with lower dose mammography  
K. Ridder; Dortmund/DE  
Purpose: After evaluating the study we published last year about “Dose saving 
and image quality of digital mammography acquired without anti-scatter grid in 
combination with a novel software-based scatter correction (SBSC)”, we 
validated the effects of this technique in our daily routine in breast imaging. 
Methods and Materials: Therefore, we compared the Image acquisition, 
dosage and image quality of actual patients who underwent a mammogram 
with PRIME technology and SBSC with prior examinations, done on the same 
Inspiration machine before. Results: The results showed a significantly 
reduced dosage of all examined patients with at least the same or even better 
image quality with PRIME technique, without any loss of information or 
prolonged examination/computing time. Conclusion: Prime technology with 
SBSC enables you to produce very high image quality at the lowest radiation 
dose without any disadvantages in routine workflow.  
Panel discussion  
 
16:00 - 17:00 Studio 2014  
organised by Siemens Healthcare  
SY 6  
Advanced multimodality breast image 
reading  
Moderator  
C. Van Ongeval; Leuven/BE  
Place of digital breast tomosynthesis in diagnostic investigation of breast 
lesions  
L.J. Pina Insausti; Pamplona/ES  
Digital Breast Tomosynthesis (DBT) is an emerging technique that has 
improved the accuracy of Digital Mammography (DM). In particular, it has been 
proven that DBT significantly increases the detection rate of breast cancers. 
Two main scenarios can be considered for the use of DBT: Problem solving 
technique: DBT can play an important role as a complementary technique for 
the evaluation of lesions detected on DM. DBT can reduce the recall rate and 
can reclassify BI-RADS 0 lesions to other categories based on the analysis of 
the shape and margins. The use of DBT can virtually eliminate the spot 
compressions, but not magnification views for microcalcifications. Detection of 
additional breast cancers: DBT can improve the sensitivity of DM, detecting 
additional breast cancers that are not visible on conventional DM. This 
technique is especially useful in dense breasts, where the sensitivity of DM is 
low. It is not reasonable to perform DBT for fat breasts because the sensitivity 
of DM is very high. A lesion needs to be surrounded by at least a small amount 
of fat to be visible on DBT. This is why some lesions can be hidden in very 
dense breasts (ACR pattern 4) even for DBT. Ultrasound is also capable of 
detecting occult cancers, and more studies are needed to compare both 
modalities.  
Learning Objectives: 
1. To show the different indications to perform digital breast tomosynthesis 
(DBT). 
2. To learn about the semiology of the lesions detected by DBT. 
3. To understand the advantages of complementary DBT. 
Place of breast MRI in diagnostic investigation of breast lesions  
E. Wenkel; Erlangen/DE  
Breast MRI as a highly sensitive tool for cancer detection has become an 
accepted method in breast imaging among mammography and ultrasound. 
Several indications are widely accepted like screening women at high risk of 
breast cancer, occult primary breast cancer, search for recurrent disease in 
inconclusive mammography and ultrasound. However, MRI is often not 
available for women due to different reasons like reimbursement from health 
insurances or lack of scanners. More recent developments like tomosynthesis 
claim to replace conventional mammography. Hence each modality is not 
suitable for every patient or maybe not every patient needs all available 
imaging modalities. On the basis of clinical examples with the focus on 
recurrent disease we want to discuss the different imaging methods dependent 
on the patient’s clinical history, breast density and histology.  
Learning Objectives: 
1. To discuss different approaches to detect (recurrent) breast cancer. 
2. To learn criteria to distinguish between benign and malignant breast lesions. 
3. To discuss the different imaging modalities for different patients. 
Panel discussion  
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Friday, March 7 
12:30 - 13:30 Room B  
organised by Toshiba Medical Systems  
SY 7  
Adaptive diagnostics: solving clinical 
challenges 
Moderator  
D. Hahn; Berlin/DE  
A new reconstruction algorithm: single energy metal artefacts reduction 
(SEMAR), applied for evaluation of hip protheses  
P.A.G. Teixeira; Nancy/FR  
Total Hip Arthroplasty (THA) is frequently performed for the treatment of 
advanced degenerative joint disease of the hip. Complication rates are low but 
the great number of hip prosthesis implanted renders radiologists prone to be 
confronted to post surgical peri prosthetic complications. Radiography remains 
the first step to assess a THA but CT-scans, MRI and sonography are now 
complementary tools that might be useful for the etiological diagnosis of a 
painful THA. Common indications for CT of THA are a painful hip prosthesis 
with normal radiographic findings, the assessment of osteolysis before surgical 
revision, the evaluation of soft tissues complications and the measurement of 
acetabular cup placement. Classic CT-scan is hampered by metal artifacts and 
is responsible for high radiation dose to the patient. Soft tissues anomalies are 
hardly seen with classic CT-scan. When optimized to reduce metal artifacts 
using suitable acquisition techniques and new algorithms, CT-scan is the most 
polyvalent technique to assess the components of the prosthesis, the cement 
and the bone interface, the bone stock and the soft tissues. These new 
algorithms: iterative reconstruction (AIDR 3D) and metal artifact reduction 
(SEMAR) software improve the image quality while reducing the dose. The 
objective of this presentation is to show how to improve prosthesis evaluation 
with CT scan. 
Lung subtraction versus dual energy  
M. Prokop; Nijmegen/NL 
Pulmonary embolism with CT is a great challenge because small thrombi can 
easily be missed (many small arteries), differentiation partial volume making 
real embolus difficult. Furthermore, reduced lung perfusion almost invisible on 
standard CT. In this lecture, we will look into Dual Energy and Subtraction 
imaging techniques to detect perfusion defects, to help localise small emboli, 
and to increase a prognostic value. Both advantages and down sides of each 
method will be analysed and presented.  
 
12:30 - 13:30 Room D  
organised by Bayer HealthCare  
SY 8  
Advances in contrast enhanced MRI  
Moderators  
M.F. Reiser; Munich/DE  
B. Song; Chengdu/CN 









12:30 - 13:30 Room E1  
organised by Guerbet  
SY 9  
When contrast innovation drives the safety 
of the patient  
Moderator  
M. Dewey; Berlin/DE  
Introduction  
M. Dewey; Berlin/DE  
MR-guided biopsy in breast cancer: when interventional MRI and 
macrocyclic contrast media are companions for a safe patient follow-up  
K. Pinker-Domenig; Vienna/AT  
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the 
breast is the most sensitive method for detection and staging of breast cancer 
providing both morphologic and functional information. DCE-MRI is widely 
used not only for diagnosis and staging, but also assessment of the treated 
breast and image-guided interventions. This presentation aims to provide a 
comprehensive overview on the indications of DCE-MRI in patients prior to and 
after breast cancer therapy, to become familiar with the DCE-MRI features of 
the treated breast and to learn about MR image-guided interventions in case of 
suspected recurrence.  
X-act in cardiac CT: results of a multicenter randomised study towards 
better patients’ safety through low radiation and iodine dose  
M. Dewey; Berlin/DE  
The aim is to compare the evaluability of coronary computed tomography (CT) 
angiography scans using three iodinated contrast agents with different 
concentrations in a multicenter non-inferiority phase-IV trial including patients 
with suspected coronary artery disease. From November 2010 until September 
2012, 468 patients underwent coronary CT angiography in 24 European 
centers. The primary outcome was the evaluability of CT based upon the 
grading of 18 coronary segments per patient for quality and interpretability of 
images. Out of the 468 patients included (57.8±12.4 years, 57.7% male, 
77.5±15.5 kg, 61.6± 9.2 bpm), 452 patients were available for the primary 
analysis. Randomisation efficiently balanced all patients’ baseline 
characteristics and resulted in 151, 152, and 149 patients undergoing CT using 
Xenetix 350, Ultravist 370, and Iomeron 400. The non-inferiority was 
demonstrated for the primary outcome per-patient evaluability for Xenetix 
(92.1%) when compared with Ultravist (95.4%) and Iomeron (94.6%), 
respectively (p<0.05 for testing difference vs non-inferiority margin). There 
were no significant differences between the three groups regarding safety and 
efficacy (image quality, stenosis, assessment, and signal quantification), and 
regarding overall amount and flow of contrast agent (79.5±9.6ml @ 
5.3±0.7ml/s, 79.1±10.2ml @ 5.2±0.7ml/s and 79.2±9.4ml @ 5.2±0.7ml/s 
respectively for Xenetix, Ultravist and Iomeron (p<0.94, p<0.49)). The mass of 
iodine (in g) injected was significantly lower for Xenetix (27.8±3.4) than 
Ultravist (29.3±3.8) and Iomeron (31.7±3.8), p<0.001. In conclusion, Coronary 
CT angiography using Xenetix 350 is non-inferior to higher concentration 
contrast agents regarding image quality and evaluability while the amount of 
iodine required can be significantly reduced.  
TACE in HCC: cone beam CT and arterial feeders detection improves 
patient survival  
H. Kobeiter; Paris/FR  
Cone-beam computed tomography (CBCT) has already proven its worth when 
used during intra-arterial therapy for liver cancer and is therefore likely to 
become indispensable as an imaging tool during transarterial 
chemoembolisation. CBCT provides three-dimensional (3D) volumetric 
information that is critical for the three main TACE steps: tumour localisation, 
planning and guidance for catheterisation, and intra-procedural evaluation of 
treatment success. CBCT technology is rapidly evolving along with the 
development of multiphasic-CBCT imaging techniques, which combine various 
CBCT acquisitions and intra-arterial contrast injection. In particular, the dual-
phase CBCT_(DP-CBCT) technique has improved tumour detection accuracy 
to the point that it is now approaching that of diagnostic imaging. By providing 
3D-hepatic arterial anatomy information, DP-CBCT can help catheter 
navigation to reach the targeted tumour. The availability of a DP-CBCT is 
advantageous also for planning of therapy delivery and guidance during 
catheterisation: A)The first phase to define hepatic arterial anatomy B)The 
second phase to accurately identify the boundaries of the targeted tumour. 
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Automated software facilitates the identification of tumour feeding arteries and 
provides a 3D-roadmap. DP-CBCT imaging can also be used for intra-
procedural assessment of treatment success because it is highly predictive of 
tumour response with follow-up MR imaging. CBCT imaging has been shown 
to predict tumour response on the post-treatment follow-up diagnostic imaging 
and to be an independent factor associated with longer overall survival after 
TACE. In conclusion, CBCT is becoming an essential and indispensable tool in 
interventional oncology.  
Questions and conclusions  
M. Dewey; Berlin/DE  
 
12:30 - 13:30 Room F2  
organised by Siemens Healthcare  
SY 10  
Leading. With MAGNETOM.   
Programme not available by date of print 
 
12:30 - 13:30 Room G/H  
organised by Bracco  
SY 11  
Breast MRI: how to make it available to 
more patients  
Moderator  
T.H. Helbich; Vienna/AT  
Introduction: shaping the future of breast MRI  
T.H. Helbich; Vienna/AT  
Breast MRI and other diagnostic tools  
F.J. Gilbert; Cambridge/UK  
Identifying patients that can benefit from MRI  
F. Sardanelli; Milan/IT  
Optimising MRI scanning protocols for breast cancer screening  
C.K. Kuhl; Aachen/DE  
 
12:30 - 13:30 Room I/K  
organised by GE Healthcare  
SY 12  
Latest advances in cardiac MR  
Moderator  
J.-L. Sablayrolles; St. Denis/FR  
GE vision for cardiac MR  
A. Brau; Munich/DE  
Ischemic cardiac disease: the role of cardiac MR vs other imaging 
modalities  
G. Pontone; Milan/IT  
Quantitative MR imaging of myocardial fibrosis  
E. Mousseaux; Paris/FR  
 
 
12:30 - 13:30 Room L/M  
organised by Mallinckrodt 
Pharmaceuticals  
SY 13  
Optimising image quality: does 
OptiBolusTM change the paradigm? 
Moderator  
T.J. Vogl; Frankfurt a. Main/DE  
Introduction and OptiBolusTM basics  
T.J. Vogl; Frankfurt a. Main/DE  
OptiBolusTM in liver and abdominal imaging  
T.J. Vogl; Frankfurt a. Main/DE  
Cardiovascular CT with OptiBolusTM  
C. Loewe; Vienna/AT  
OptiBolusTM in rare and unusual indications  
C. Saade; Beirut/LB  
Panel discussion  
 
12:30 - 13:30 Studio 2014  
organised by Hitachi Medical Systems 
Europe  
SY 14  
Ultrasound solutions clearly defined  
Moderator  
P. Sidhu; London/UK  
Clinical impact of-high resolution technologies in everyday ultrasound 
clinical practice  
F. Calliada; Pavia/IT  
Aim of the presentation is to introduce examples of clinical cases prepared 
using Hitachi Aloka Medical ultrasound systems. The abdominal high 
resolution imaging permitted us to evaluate even the more subtle parenchymal 
differences in the liver and kidneys. Colour Doppler with and without eFLOW 
facilitated the detection of flow, both in cases of deep and difficult vascular 
abnormalities and in the presence of detail-rich superficial, low velocity, 
vascular flow. CEUS allowed us to increase the specificity of ultrasound B-
mode enabling us to assess the micro-vascular patterns of lesions of the liver 
and kidney. The extreme high resolution of the Hitachi Aloka Medical matrix 
probes allowed us to study superficial structures with incredible detail both in 
MSK and neck pathologies and the diagnostic accuracy was further increased 
by the use of Hitachi Real-time Tissue Elastography in addition to the Doppler 
and CEUS. 
A new stage of real-time tissue elastography 
K. Nakashima; Okayama/JP 
Real-time tissue elastography for breast has become a very popular ultrasound 
tool in Japan, not only for diagnosis but also in monitoring treatments. Many 
Japanese physicians and radiologists have experience of the usefulness of 
breast elastography in daily clinical examination. Today, many ultrasound 
manufacturers support different elastography methods which include strain 
imaging and shear wave imaging. In order to introduce some standardisation, 
guidelines on the clinical use of elastography in breast examinations will be 
published by WFUMB. The most useful diagnostic tool for elastography of the 
breast is the FLR (Fat Lesion Ratio) measurement. And, as a further 
development, the function of assist strain ratio has been proposed for the 
purpose of automatic FLR measurement. My presentation will describe the 
WFUMB guidelines and a new stage of real-time tissue elastography including 
the evaluation of assist strain ratio. 
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MRI and ultrasound fusion in MSK pathology: the art of studying 
structures in static and motion  
A. Guermazi1, J. Renoux2; 1Boston, MA/US, 2Paris/FR  
MRI is widely used in musculoskeletal pathology. However, ultrasound offers 
unique advantages of high spatial resolution, real time dynamic scanning and 
ease of vascular exploration. real time virtual sonography (RVS) which 
synchronises MRI and ultrasound images can display information from both 
modalities at the same time using magnetic navigation. This new technique is 
promising in musculoskeletal imaging since ultrasound scanning is facilitated 
by MRI anatomical information helping radiologists to visualise difficult 
anatomy. Dynamic ultrasound may provide real time functional information 
about pathology seen on MRI such as mobility of knee meniscal flaps within 
articular recess or synovial plicae. Other indications for RVS include evaluation 
of peri-prosthetic pathologies by ultrasound using MRI-based anatomical 
landmarks. Finally, ultrasound-guided interventions coupled with MRI contrast 
resolution may result in higher procedure accuracy and lower morbidity. 
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Saturday, March 8 
12:30 - 13:30 Room D  
jointly organised by Siemens Healthcare 
and Bayer HealthCare 
SY 15  
Synergies in CT for better patient care  
Moderator  
A. Mahnken; Marburg/DE  
Programme not available by date of print  
 
12:30 - 13:30 Room E1  
organised by Toshiba Medical Systems  
SY 16  
Expanding clinical boundries in 
ultrasound  
Moderator  
V. Mitkov; Moscow/RU  
Genitourinary ultrasound: advanced diagnostics in prostate cancer and 
scrotal lesions  
T. Fischer; Berlin/DE  
Prostate: Men with an elevated serum level of prostate-specific antigen (PSA) 
or suspicious findings on digital rectal examination (DRE) are examined by 
transrectal ultrasound (TRUS). For histological confirmation and therapeutic 
planning, ultrasound guided systematic biopsy of the prostate is performed. 
However, in a subgroup of patients with elevated PSA levels, no malignancy is 
detected by biopsy or up to four biopsies are performed before prostate cancer 
is detected. A negative biopsy therefore does not exclude prostate cancer. In 
consequence, unnecessary biopsies with an increase of complications are 
performed in healthy men. Real-time MR/US image fusion may enhance 
cancer detection rates of TRUS-guided biopsies and contributes to lesion 
characterisation by state-of-the-art US techniques. The study presented here 
for the first time compares state-of-the art US techniques after contrast medium 
administration with MRI and histology as the standard of reference. Scrotum: 
Ultrasound is the imaging modality of choice for the examination of the 
scrotum. The propblem of tumour / haematoma misinterpretation can result in 
unnecessary orchiectomy. CEUS for the testis can be currently recommended 
for the differentiation between hypovascular and avascular lesions (benign). 
Learning Objectives: 
1. To investigate whether multiparametric magnetic resonance imaging (MRI) 
allows lesion localization in prostate cancer in patients scheduled for MR/US 
fusion biopsy and whether the findings correlate with new ultrasound 
techniques. 
2. To understand why prostate lesions were classified on the basis of MRI and 
US (B-mode scan, power Doppler, elastography/TDI, CEUS). 
3. To understand why targeted biopsies were performed in the MR/US 
fusionmode. 
4. To learn about indications for the use of CEUS in focal testicular lesions, 
secmental infartion, after trauma and abscess formation in severe 
epididymoorchitis. 
Abdominal and high-frequency ultrasound imaging: latest technologies 
for improved lesion detection and characterisation  
A. Lim; London/UK  
This talk will encompass the latest technological developments of the Aplio 500 
with particular focus on a few advanced applications for abdominal and small 
parts ultrasound. These newest developments include the improved 
visualisation of the microvasculature without the need for contrast and its 
potential clinical applications will be discussed. There have also been 
significant improvement in specialist applications such as elastography and 
also improved sensitivity in high frequency contrast technology. The latter now 
also allows reliable detection of the sentinel lymph node and their clinical 
impact will be outlined and illustrated. 
Seeing the unseen: new clinical findings by novel imaging techniques  
J. Hata; Kawasaki/JP  
In this session, the clinical experience of Superb microflow imaging (SMI), 
which is the novel application of Aplio 500 from Toshiba, is discussed. SMI is a 
unique ultrasound Doppler imaging employing multi-dimensional filter that 
makes it possible to depict minute vessels with slow velocity, without using 
contrast agents. In other words, the advantages of SMI are; 1.high frame rate, 
2. high sensitivity, 3. high resolution, and 4. less motion artifact. Therefore, SMI 
is useful in various situations encountered in daily practice. The evaluation of 
the density and the shape of tumor vessels with SMI help us diagnose and 
differentiate tumorous lesions and also could be the non-invasive modality for 
the assessment of therapeutic effect of chemotherapy. Since SMI clearly 
visualises minute vessels, it can also be used to evaluate the disease activity 
in inflammatory disorders, even in bowel inflammation such as ulcerative 
colitis, Crohn’s disease, and so forth. Furthermore, the diagnosis of organ 
ischemia can be done accurately with SMI, which is expressed as the focal 
defect of minute vessels in a real-time fashion, with high spatial resolution. In 
addition, SMI provides more sensitive view of minute vessels after the injection 
of contrast agent, which helps us to obtain the sustained dynamic image of 
microflow even after the first pass of the contrast agent. In conclusion, SMI, 
which provides the dynamic image of microvessels, is an essential tool for the 
diagnosis and the evaluation of various clinical conditions.  
 
12:30 - 13:30 Room F2  
organised by GE Healthcare  
SY 17  
Developing innovative breast care 
solutions to improve clinical confidence  
Moderator  
D.B. Kopans; Boston, MA/US  
Breast tomosynthesis in diagnostic work-up  
A. Stork; Düsseldorf/DE  
EASY study: integration of automated 3D breast ultrasound (ABUS) into 
the routine workflow of a high-volume hospital-based breast cancer 
screening program in Stockholm, Sweden  
B. Wilczek; Stockholm/SE  
Role of MRI in the breast cancer pathway in challenging situations  
C.S. Balleyguier; Villejuif/FR  
 
12:30 - 13:30 Room G/H  
organised by Bracco  
SY 18  
Personalising an integrated approach to 
CT imaging  
Moderator  
C.J. Herold; Vienna/AT  
Personalised CT imaging: are we there yet?  
M. Francone; Rome/IT  
Low Kvp protocols: what you should know  
T. Albrecht; Berlin/DE  
An integrated approach: what more is needed?  
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12:30 - 13:30 Room I/K  
organised by Samsung Medison  
SY 19  
A new technology for detecting and 
diagnosing: ultrasound breast CAD and 
ElastoScan quantification 
Introduction of breast ultrasound CAD 
Advances in CAD for diagnosis of breast cancer 
Breast cancer detection with ElastoScan quanitification 
Questions and answers 
 
12:30 - 13:30 Room L/M  
organised by Siemens Healthcare  
SY 20 
Pioneering the future of ultrasound 
Moderator  
P.S. Sidhu; London/UK  
ARFI technique reproducibility and role in chronic liver disease: are we 
ready to replace liver biopsy?  
P.S. Sidhu; London/UK  
Ultrasound imaging of liver disease has until recently been restricted to a 
qualitative assessment of the parenchyma, visualisation of focal lesions and 
the establishment of bile duct dilatation. Subjective opinion of the presence of 
liver fibrosis is unreliable, advanced cirrhosis is often a clear sonographic 
diagnosis. Measurements of Doppler parameters to ascertain the presence of 
parenchymal disease have largely been disappointing; quantitate assessment 
being too variable for clinical consistency. Microbubbles generally have not 
been a success in the evaluation of diffuse liver disease using ‘transit’ times to 
the hepatic veins; although targeted microbubbles to elements of fibrotic 
change are a reality. Quantification of liver ‘stiffness’ using non-invasive 
methods, primarily Acoustic Radiation Force Impulse (ARFI) imaging are 
promising in assessing liver stiffness and indirectly liver fibrosis and cirrhosis. 
The possibility of employing this technique to assess patients for liver biopsy is 
gaining momentum. The reproducibility of measurements has been 
demonstrated and the ability to categorise different levels of fibrosis and hence 
the clinical management is now a reality. The capability to demonstrate 
‘normality’ or ‘severe fibrosis’ is accurate with the number of liver biopsy 
procedures reduced, directly and ultimately patient morbidity is reduced. There 
is acceptable application of this technique in clinical practice in many centres 
dealing with chronic liver disease. This lecture will describe the usefulness of 
ARFI in clinical practice, with the ability to confidently triage patients into the 
various categories that genuinely influence clinical management. 
Learning Objectives: 
1. To understand why a non-invasive test for liver fibrosis is important.  
2. To appreciate the technique of ARFI measurement’s and the limitations.  
3. To consolidate knowledge and apply ARFI into clinical practice. 
Clinical benefits of fusion imaging and a new contrast software (CHI)  
A. Nilsson; Uppsala/SE 
The ability to fuse a current ultrasound examination with another imaging 
modality means that lesions seen on a previous CT or MRI can be found with 
ease, characterised, biopsied and possibly treated, all under ultrasound 
guidance. This increases the diagnostic accuracy and in many cases saves 
time and resources. The advent of a new contrast software (CHI) with an 
improved spatial resolution means that smaller lesions can be detected. CHI 
also enables an extension of the contrast late phase up to 6-7 minutes. This 
gives us more time to find metastatic lesions with a late phase wash-out and 
possibly means that lesions until now thought to have no wash-out within the 
usual timeframe, like hepatocellular carcinomas, can be assessed. 
Learning Objectives:  
1. To understand the principles of CT and MRI image fusion with ultrasound.  
2. To appreciate the clinical and practical benefits of ultrasound fusion.  
3. To understand the benefits of contrast harmonic imaging and where it is 
useful in clinical practice. 
Virtual touch tissue imaging quantification (VTIQ): a new tool to measure 
breast tissue stiffness and for breast lesion assessment by ultrasound  
M. Golatta; Heidelberg/DE 
 
Purpose: To evaluate breast tissue stiffness with Virtual touch tissue imaging 
quantification (VTIQ) and to prospectively evaluate VTIQ as a new 
elastography method concerning its intra- and inter-examiner reliability, its 
ability to differentiate benign from malignant breast lesions in comparison to 
and in combination with B-mode BIRADS® assessment. 
Methods and Materials: B-mode ultrasound and VTIQ were performed 103 
women with 104 lesions. Mean values of VTIQ for parenchyma and fatty tissue 
were compared between those measured in healthy breasts and in the 
surrounding of histologically proven benign and malignant lesions. Intra- and 
inter-examiner reliability of VTIQ were assessed. BIRADS® assessment was 
applied prior to VTIQ. The AUC, sensitivity, specificity, PPV and NPV of 
BIRADS®, VTIQ and combined data were compared. 
Results: The mean VTIQ values in parenchyma were significantly higher than 
in fatty tissue (3.23m/s ± 0.74 versus 2.5m/s ± 0.61;p<0.0001). In healthy 
breasts as well as in the surrounding of a benign or malignant lesion the VTIQ 
values of parenchyma and fatty tissue were similar. 54 of 104 lesions were 
malignant. Intra-examiner reliability was consistent, inter-examiner agreement 
showed a strong positive correlation assessed with orthogonal regression. The 
mean VTIQ-values in malignant lesions were significantly higher than in benign 
(7.73m/s ±1.02 versus 4.46m/s ±1.87;p<0.0001). The combination of US-
BIRADS® with the optimal cut-off for clinical decision making of 5.18m/s, 
yielded a sensitivity of 98%, specificity of 82%, PPV of 86% and NPV of 98%. 
Conclusion: VTIQ is a reliable method for measuring the stiffness of breast 
tissue. There is a significant difference regarding the mean maximum velocity 
of benign and malignant lesions. Adding VTIQ to BIRADS® assessment 
improves the specificity. 
Learning Objectives:  
1. To become familiar with a new elastography technique - VTIQ. 
2. To understand that standard breast lesion assessement using the BIRADS® 
can be improved by adding VTIQ. 
 
12:30 - 13:30 Room N/O  
organised by Philips  
SY 21  
Redefining image quality in CT  
Moderator  
L. de Vries; Best/NL  
Advances in iterative model based reconstruction  
R. Siemund; Lund/SE  
Optimisation of radiation dose vs image quality is a constant challenge for CT 
technology. Dose reduction with maintained diagnostic image quality was in 
the past mainly achieved by improvement of the scanner hardware e.g. 
improved detector technology and optimised signal chain. Introduction of 
mainly statistic based iterative reconstruction techniques, like iDose4, improves 
image quality by artifact reduction in the projection space and by advanced 
noise reduction in the image space, enabling dose reduction depending on 
body region and examination type. However the potential for dose reduction 
when using statistically based iterative reconstruction on already dose 
optimised protocols is limited and the resulting images are still noisy. Iterative 
Model Reconstruction (iMR) is a new type of advanced iterative algorithm 
using complex modeling of the data acquisition process and the scanner 
geometry in order to minimise noise and artifacts. Initial experience with iMR in 
clinical use and from phantom studies demonstrates impressive improvements 
in image quality: a) low noise levels regardless of radiation doses b) preserved 
low contrast resolution with reduced doses or markedly improved low contrast 
resolution at same dose levels as compared to iDose c) no smearing of 
structural information as in high level statistic based iterative reconstruction. 
These improvements enables simultaneously significant radiation dose 
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Learning Objectives: 
1. To become familiar with iterative model reconstruction, which is a major leap 
in noise reduction and improvement in low contrast detectability compared to 
statistic based iterative reconstruction. 
2. To learn about image quality improvements achieved by iterative model 
reconstruction enables further radiation dose reduction, routinely use of thinner 
slices or narrower windows width. 
Novel applications of spectral detector CT  
J. Sosna; Jerusalem/IL  
In existing tube-based dual-energy CT (DECT), dual-energy protocols must be 
prescribed prospectively, before the scan is performed, in order to select tube 
voltage or operate the two tubes at different kVp values. As clinical use of dual 
energy CT devices expands, radiologists are thus forced to determine in 
advance cases in which dual-energy analysis may be beneficial, based solely 
on the indications for study. However, when DECT data is acquired using a 
novel system designed to enable simultaneous acquisition of high-energy and 
low-energy data, the radiologist can retrospectively select spectral DECT 
protocols and reconstruct DECT images after the study has been performed. 
The system uses a single X-ray tube with dual-layer detector which performs 
spectral separation at the detector level and not by the X-ray tube. 
Simultaneous spectral detector CT (SDCT) data can be used to retrospectively 
generate virtual mono-energetic images at any selected keV in a range of 55-
200 keV. The virtual low keV imaging with its increased enhancement 
capabilities and the high KeV mono-energetic images with reduced beam 
hardening artifact allow better evaluation of findings. Material decomposition 
images and Iodine concentration maps allow direct quantification of material 
concentration. A single contrast-enhanced DECT study can be performed and 
VNC images can then be generated to simulate the non-enhanced phase, 
reducing the radiation dose to the patient.  
Learning Objectives: 
1. To discuss the different techniques of dual energy CT imaging. 
2. To discuss the potential added benefit of retrospective spectral 
reconstruction. 
3. To demonstrate clinical applications of spectral detector CT.  
 
12:30 - 13:30 Studio 2014  
organised by Philips  
SY 22  
A new era in premium ultrasound  
Moderator  
J.-M. Correas; Paris/FR  
General and paediatric radiology using the EPIQ system  
M. Claudon; Vandoeuvre-les-Nancy/FR  
The EPIQ system is a new generation of ultrasound platform, built around a 
new precision beamformer and massive parallel processing, resulting in high 
detailed images, tissue detail uniformity at high frame rates. New probes, such 
as a curved C9-2 MHz array allow a penetration up to 15 centimeters, 
maintaining high quality and uniformity of images. In addition to volume 
imaging performed at high frame rate with matrix probes, panoramic volume 
imaging can be achieved, extending the possibility to better display the 
anatomy of organs and lesions. This new system can have direct access to 
multimodality images, allowing retrieving previous multimodality images for 
immediate comparison of size, extension and patterns of lesions, and offers 
the possibility to upload all the reconstructed data to the patient’s file. Our first 
months of daily experience with EPIQ system, in an adult and paediatric 
population, will be reported and illustrated by cases on abdominal pathology, 
including liver, native and transplanted kidney, and on vascular imaging.  
Learning Objectives: 
1. To understand how technology integrated in the new EPIQ system is useful 
in general and paediatric imaging. 
2. To learn about expert’s first months of daily experience with EPIQ system. 
3. To appreciate the benefits that can be gained by using this new US platform 
in terms of diagnosis and workflow efficiency. 
Fusion navigation: expanding the role of ultrasound in radiology  
D.A. Clevert; Munich/DE  
Current clinical studies have demonstrated the excellent diagnostic 
performance of contrast-enhanced ultrasound (CEUS) in the detection and 
characterisation of benign and malignant hepatic tumours in correlation with 
histology and standard imaging techniques such as contrast-enhanced 
computed tomography (ceCT), contrast-enhanced magnetic resonance 
imaging (ceMRI), as well nuclear medicine modalities such as positron-
emission tomography (PET) and PET-CT. New developments are based on 
the 3D or 4D assessment of the microcirculation using CEUS and the 
acquisition of CEUS images in parallel with images from other modalities, 
particularly ceCT and ceMRI, using image fusion and volume navigation. 
Through the use of high-resolution multi-frequency transducers, Matrix 
transducers and high-frequency linear transducers, the diagnostic spectrum of 
CEUS is continually expanding. This is also shown in the current, recently 
published CEUS guidelines for non-hepatic applications, which review several 
studies and future developments, demonstrating the wide diagnostic spectrum 
of CEUS. For image fusion a magnetic field generator and a corresponding 
probe sensor are requested as hardware components. Additionally, dedicated 
software must be installed on the ultrasound system. The probe sensor is 
detected by a magnetic positioning system, which calculated the exact position 
of the sensor in the room. Standard DICOM data sets of all cross-sectional 
modalities (CT, MRI, PET-CT/MRI) may be used for image fusion. The DICOM 
data are loaded in the ultrasound system, following which a registration of the 
datasets takes place. This registration can be performed based on a number of 
fixed reference points or by plane. After a successful image fusion, the 
registered MRI or CT image are seen to move simultaneously with the 
examined ultrasound imaging plane. There is also the option of viewing the 
registered images either in overlay mode or side-to-side mode. The standards 
ultrasound options like colour Doppler and CEUS may be easily integrated in 
the fused images. Thus, the simultaneous assessment of tumour 
vascularisation and complex vascular pathologies using CEUS in parallel with 
information from ceCT and ceMRI images is possible. In this symposium new 
ultrasound technique like image fusion and navigation will be discussed in the 
clinical settings.  
Improved detail resolution in MSK ultrasound using high frequency 
imaging  
C. Martinoli; Genoa/IT  
 
14:00 - 15:30 Room C  
organised by Hologic The Women’s 
Health Company  
SY 23  
Breast tomosynthesis: evolution and 
adoption across Europe  
Moderator  
A. Smith; Bedford, MA/US  
Programme not available by date of print  
 
14:00 - 15:30 Room E1  
organised by Olea Medical  
SY 24  
Moderator  
S. Pedraza; Girona/ES  
Introduction  
S. Pedraza; Girona/ES  
Theory and practice of brain perfusion  
A. Davis; New York, NY/US  
Clinical applications of neuroimaging perfusion  
M. Essig; Winnipeg, MB/CA  
Summary and discussion  
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14:00 - 15:30 Room I/K  
organised by Philips  
SY 25  
Addressing today’s challenges with next 
generation digital MR solutions  
Moderator  
J. van den Heuvel; Eindhoven/NL  
Addressing today’s challenges with next generation digital MR solutions  
J. van den Heuvel; Eindhoven/NL  
New perspectives on speed and robustness in MRI with Ingenia 1.5T  
T. Leiner; Utrecht/NL  
Learning Objectives: 
1. To understand key, synergistic advances in MR scanning hardware and 
software present on the Ingenia MRI scanner. 
2. To demonstrate how these advances can be leveraged to improve image 
quality of existing protocols. 
3. To demonstrate how these advances can be leveraged to improve imaging 
speed and patient throughput. 
Innovations in neuro imaging on the new Philips 3T dStream platform  
S. Van Cauter; Leuven/BE  
The diagnosis and follow-up of patients with gliomas relies mainly on magnetic 
resonance imaging (MRI). However, routinely used MRI techniques still present 
many difficulties in clinical practice. Current conventional MRI techniques are 
insufficient to define glioma grade. Moreover, in the follow-up of patients with 
glioblastoma, the differentiation between therapy-induced inflammatory 
reactions and early tumour relapse remains challenging. Currently used 
conventional MRI techniques do not enable adequate documentation of the 
nature of the tumoural pathophysiology of gliomas. Advanced MR methods, 
however, address parameters like diffusion, tissue organisation, blood flow or 
metabolism, induced by pathology. Therefore, advanced MR techniques 
potentially provide more insights in the problems encountered with the 
currently used conventional MR techniques. Diffusion MRI allows non-invasive 
mapping of the diffusion process of water molecules in a biological 
environment. Measures of the vascularity of brain tissue, using perfusion MRI, 
provides markers of blood flow and blood volume in healthy and diseased 
tissue. Chemical shift imaging (CSI) can be used to study the metabolism of 
gliomas. For example, CSI provides markers of neuronal density, cell turn over 
and energy metabolism.  
Learning Objectives: 
1. To show how these advanced MRI techniques can benefit an accurate 
diagnosis in brain tumours, using data acquired on a new Philips 3T system 
with dStream technology (digital coils). 
2. To understand how advanced MRI techniques can be combined into a 
comprehensive acquisition protocol, implementable in clinical practice. 
3. To appreciate how the acquired data is conveniently processed with the 
advanced Philips software. 
 
14:00 - 15:30 Room L/M  
organised by GE Healthcare Nycomed 
Distribution LLC  
SY 26  
Interdisciplinary approach to current 
issues of abdomen radiology  
Moderators  
V.N. Kornienko; Moscow/RU  
V.E. Sinitsyn; Moscow/RU  
Clinical guidelines and practical contrast media usage  
I. Tyurin; Moscow/RU  
 
urrent approaches to evaluation of focal liver lesions  
A. Lukianchenko; Moscow/RU  
Pre-operative imaging in abdominal oncology: what does a surgeon need 
from a radiologist?  
V.K. Lyadov; Moscow/RU  
Russian radiology best practice: clinical experience sharing  
S.U. Kim1, Y.I. Nerestyuk1, I.M. Archipova1, M.V. Vishnyakova1, A. Surmava2; 
1Moscow/RU, 2Novosibirsk/RU 
Discussion  
Please note that the symposium will be held in Russian; simultaneous 
translation supplied on behalf of the organizers. 
 
14:00 - 15:30 Room N/O  
organised by Philips  
SY 27  
Low dose and spectral imaging, a new era 
in mammography  
Moderator  
M. Danielsson; Stockholm/SE  
Experience of low dose photon counting mammography and spectral 
breast density measurement  
E. Cauzza; Bellinzona/CH  
Breast density is a risk factor for breast cancer and an indicator for the 
sensitivity of mammography (masking). A breast density measurement could 
be a starting point for a personalised screening plan with for example tailored 
screening interval and choice of imaging modality. Dual energy imaging is 
today a reference for body composition measurements. Non-contrast spectral 
mammography brings this technology to breast imaging with potential 
improvements in accuracy compared to existing image processing based 
methods. We report on our experience using spectral mammography in our 
clinical practice and present data on dose reduction and performance 
indicators of the spectral breast density measurement.  
Spectral lesion characterisation: will it be possible to distinguish cysts 
from solid masses on the screening mammogram?  
F. Kilburn-Toppin; Cambridge/UK  
Non-contrast spectral mammography could potentially be used to better 
characterise cysts in mammography, and thereby reduce unnecessary recalls 
based on mammography screening results. We have conducted a pilot study 
using a photon counting spectral mammography unit from Philips to investigate 
the feasibility of lesion characterisation. Data from the pilot study have been 
used to refine the characterisation algorithm and viewing protocol and results 
are in line with expected values.  
Future applications of photon counting spectral mammography  
M. Åslund; Solna/SE  
Photon counting spectral mammography has demonstrated diagnostic 
performance and dose reduction as well as shown promising results in material 
decomposition for the purpose of breast density measurement and lesion 
characterisation. This presentation will outline future potential applications of 
this unique technology with the aim to further increase diagnostic performance 
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14:00 - 15:30 Press Room 
organised by Bayer  
SY 31  
The role of FFRCT in the discrimination of 
ischemia and clinical case review  
Moderator  
M. Gutberlet; Leipzig/DE  
Clinical introduction to invasive FFR and role of invasive FFR in CAD  
B. de Bruyne; Aalst/BE  
FFRCT background and technology  
M. Gutberlet; Leipzig/DE  
FFRCT clinical data and clinical experience  
G. Pontone; Milan/IT  
Live interactive cases  
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Sunday, March 9 
12:30 - 13:30 Room C  
organised by GE Healthcare  
SY 28  
Breakthrough CT and contrast media 
innovations: game changer for patient 
care  
Moderator  
J. de Mey; Brussels/BE  
Low dose cardiac CT with 270 concentration isosmolar contrast media: 
the right choice for image quality and patient care?  
D. Andreini; Milan/IT  
Spectral imaging and Veo: clinical practice and new perspectives in 
oncology  
A. Luciani; Créteil/FR  
Sharing GE CT vision and future  
E. Stahre1, J.-L. Sablayrolles2; 1Milwaukee, WI/US, 2St. Denis/FR  
 
12:30 - 13:30 Room L/M  
jointly organised by Bracco and Philips  
SY 29  
Contrast-enhanced ultrasound (CEUS) and 
trends in technological innovation  
Moderator  
L. Solbiati; Busto Arsizio/IT  
Recent technical innovations in abdominal CEUS  
D.A. Clevert; Munich/DE  
CEUS and new tools for percutaneous interventional procedures  
J.-M. Correas; Paris/FR  
Are we using enough CEUS in clinical practice? Role in radiation dose 
reduction  
P.S. Sidhu; London/UK  
 
12:30 - 13:30 Room N/O  
organised by Bayer  
SY 30  
Whole body MRI  
Moderators  
I.N. Pronin; Moscow/RU  
V.E. Sinitsyn; Moscow/RU  
Skull base meningiomas: how much do we know?  
I.N. Pronin; Moscow/RU  
Brain meningiomas make up the most frequently encountered category of 
intracranial lesions. Diagnostics and treatment of brain meningiomas are well 
studied and mastered in neurosurgery. The most complicated group of 
meningiomas are skull base tumours. The depth of their location, peculiarities 
of blood feeding and haemodynamics as well as density of the tumour 
consistency make their neurosurgical resection rather a difficult task. 
Development and application of new non-invasive evaluation techniques of 
various pathological characteristics and peculiarities of the tumour tissue such 
as blood supply (tumour matrix), degree of malignancy, heterogeneity of the 
blood flow and density of the tumour tissue make it possible to plan surgical 
access and methods of resection and to forecast possible blood loss and 
completeness of the resection. DW and DT MRI demonstrate possibilities of 
differential diagnosis of classical and atypical meningiomas subgroups on the 
basis of ADC mapping and FA measurements. The use of high-resolution MR 
angiography on 3.0 T MRI makes it possible to evaluate skull base 
meningioma arteries' blood supply completely without direct angiography 
(DSA). Perfusion technologies (CT-, T2* MRI and ASL) demonstrate a high 
degree of information on the course of assessment of tumour haemodynamics, 
make it possible to differentiate atypical and typical variants of meningiomas 
and to forecast the degree of intra-surgical blood loss and peculiarities of 
tumour haemodynamics in different locations.  
Learning Objectives: 
1. To become familiar with DWI and DT MRI assessment of tumor degree. 
2. To learn about the evaluation of tumor feding arteries with high resolution 
3D-TOF MR- angiography. 
3. To understand methods of perfusion (CT, T2* MRI and ASL) for tumor 
hemodynamic assessment. 
4. To compare different CT and MR-techniques data and correlation with 
surgical findings. 
MR-angiography of the body: different techniques and areas of 
implementation  
E. Mershina; Moscow/RU  
Magnetic resonance angiography (MRA) is a non-invasive method with a high 
diagnostic accuracy. MRA can be performed as non-contrast or contrast 
enhanced. Non-contrast MRI can be performed with the help of time-of-flight 
(TOF) or phase-contrast (PC) pulse sequences. MRA is widely used for 
imaging of intra- and extracranial vessels, thoracic and abdominal aorta, 
pulmonary arteries, and renal and lower limb arteries. Magnetic resonance 
angiography (MRA) of the coronary arteries is still not ready for routine clinical 
application, but it is under further development and the results of clinical trials 
in this field are quite promising. For peripheral contrast-enhanced 3D MR-
angiography, paramagnetic contrast agent is administered using a biphasic 
injection protocol at a dose of 0,1-0,3 mmol/kg BW. Gd-MRA can be performed 
with moving table platform (multi-station Gd-MRA) which allows to get 
extended 3D datasets of the whole of the thoracic or abdominal aorta and its 
branches. Several coronal contiguous 40 cm data sets can be collected, each 
with a 3D gradient sequence, with the total scan time being less than 60s and 
slice thickness <1 mm. Recently, the technique of non-contrast MRA has been 
substantially improved (inflow-enhanced MRA). It can be used for example for 
visualization of renal arteries in patients with a high level of serum creatinine. 
MRA examinations are technically more demanding than CTA ones. Special 
attention should be paid to training of the radiographers performing MRA. MRA 
without radiation exposure is a good alternative to CT-angiography, especially 
in young patients and in those with impaired renal function.  
Endorectal MRI of prostate cancer: do's and don'ts review  
S. Morozov; Moscow/RU  
In the last decade, prostate MRI has moved from research to the clinical area, 
being fostered by radiologists-protagonists and supported by clinical 
oncologists and urologists. The concept of functional prostate MRI has rapidly 
become the standard of care providing radiologists with an effective diagnostic 
solution. Standardisation of image interpretation by Pi-RADS makes the results 
easily understood by urologists and oncologists. Implementation of prostate 
MR schemes mirroring that of TRUS biopsy allows direct comparison of MR 
results with histopathology. Recently developed ESUR recommendations on 
prostate MRI have contributed significantly to the wide acceptance and 
implementation of the technique. Still, many clinicians consider this study 
suitable only for cancer staging in high-risk patients, underestimating its 
usefulness for tumour diagnosis and aggressiveness estimation. This report 
provides an overview of the current prostate MR techniques and best practices 
(including multi-parametric technique, proton spectroscopy, diffusion-weighted 
and dynamic contrast-enhanced imaging), performance optimisation tricks, 
interpretation tips, major pitfalls and recent advances. The ability of MRI to 
exclude clinically significant cancers will be emphasised. The review will also 
focus on the role of MRI in active surveillance of prostate cancer and in the 
diagnosis of recurrent cancer ranging from local to regional and distant. The 
view of the urologist and radiation oncologist on prostate MRI will also be 
presented. Finally, whole body MR imaging for the early detection of 
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Modern MRI: different ways for visualisation and differentiation of the 
focal liver lesions  
G. Karmazanovsky; Moscow/RU  
Modern radiology allows noninvasively visualising and differentiating focal liver 
lesions. MDCT and MRI with contrast enhancement are used for the 
characterisation of blood supply to tumours and in differential diagnosis. Such 
techniques as ultrasound elastography, MR-elastography, and diffusion-
weighted images allow differentiating tumours without the use of contrast 
agents. Magnetic resonance imaging with liver-specific contrast agents is a 
most accurate technique for detection of small size liver metastases, 
assessment of the primary liver tumours, visualisation of a biliary tree, and 
evaluation of gallbladder function. These techniques help to assess the 
effectiveness chemotherapy of liver tumours and preoperative assessment of 
liver resection.  
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